Metformin

Methodology and it’s importance in Science 1/ Methodology is the foundation of science. It’s the blueprint for how we test ideas, gather evidence, and build knowledge. Strong methods produce reliable results that others can verify, pushing science forward. Weak methods lead to shaky conclusions that stall progress. #Science 2/ A solid methodology ensures experiments are repeatable. When scientists worldwide can replicate results, trust in findings grows. This builds a sturdy base for new discoveries, from vaccines to physics breakthroughs. Reproducibility is key to advancing human understanding. #Research 3/ Poor methodology muddies the waters. Flawed designs, biased samples, or sloppy data collection can lead to false conclusions. These missteps waste time, resources, and trust, slowing scientific progress. Good methods keep us on track for real insights. #ScienceMatters 4/ Methodology evolves with science. New tools, like advanced imaging or statistical models, refine how we study the world. Adapting methods to new challenges ‘’like studying climate or genetics’’ fuels innovation and opens new frontiers in knowledge. #ScientificMethod 5/ In short, methodology isn’t just a step it’s the engine of science. Rigorous, transparent methods drive discoveries that change lives. Cutting corners risks setbacks. #Research #Discovery $met

Science grows on cumulative knowledge, each discovery builds on the last, pushing humanity forward. From Newton to CRISPR, every step compounds our understanding. Keep questioning, keep learning! #DeScie

We are pleased to announce the initial findings from our study, “Evaluation of the Anti-Aging Properties of Metformin in a D-Galactose-Induced Aging Rat Model". @Metformin_Sol/collected-data-and-results-for-evaluation-of-the-anti-aging-properties-of-metformin-in-a-fdfe6c2099e8" target="_blank" rel="nofollow noopener">medium.com/@Metformin_Sol… $met #DeSci

D-galactose, a sugar, mimics aging by inducing oxidative stress, inflammation, and mitochondrial dysfunction. Our study explores its potential to reverse these effects and advance longevity science. Today we are going to share the pure dataset and the statistical results of the Study! $Met

We are pleased to announce the initial findings from our study, “Evaluation of the Anti-Aging Properties of Metformin in a D-Galactose-Induced Aging Rat Model.” We look forward to sharing these results with our community in the near future. $Met

@Metformin_Sol/1-introduction-to-cumulative-knowledge-8cd296afcc7a" target="_blank" rel="nofollow noopener">medium.com/@Metformin_Sol…

The Scientific Method: A Foundation for Discovery in a Connected World The scientific method is a vital process driving humanity’s greatest discoveries, from relativity to vaccines. A 2024 PNAS Nexus study, “Redefining the scientific method: As the use of sophisticated scientific methods that extend our mind,” shows 71% of 761 major scientific discoveries, including all Nobel Prize-winning findings from 1901 to 2022, followed its core principles. What is the Scientific Method? The scientific method is a systematic way to investigate the natural world. It ensures conclusions are evidence-based, not speculative. While variations exist, it typically includes: 1Observation: Noticing a phenomenon or problem. 2Question: Forming a specific question based on the observation. 3Hypothesis: Proposing a testable explanation or prediction. 4Experimentation: Conducting experiments to test the hypothesis, collecting data under controlled conditions. 5Analysis: Evaluating data to assess the hypothesis. 6Conclusion: Drawing insights, often sparking new questions. 7Communication: Sharing results for peer review and replication. The PNAS Nexus study found 94% of major discoveries involved observation, 81% hypothesis testing, and 75% experimentation, showing its consistent use across fields. The Evolution of the Scientific Method Since its origins in the 17th century with thinkers like Francis Bacon and René Descartes, the scientific method has transformed. Early emphasis on empirical observation has expanded with tools like microscopes, telescopes, and now AI and computational models. The 2024 study highlights how advanced instruments improve replicability and precision, as seen in discoveries like the Higgs boson or genomic sequencing. The method is not a fixed formula but adapts to each era’s tools and questions. Today, data-driven approaches and simulations complement traditional experiments, enhancing its flexibility. Why the Scientific Method Matters The scientific method’s strength is its ability to deliver reliable, reproducible results. Testable hypotheses and peer-reviewed findings reduce bias and ensure accountability, leading to breakthroughs like penicillin and renewable energy. The PNAS Nexus study notes 75% of discoveries since 1900 followed its principles, proving its relevance amid growing complexity. It also provide curiosity and skepticism, encouraging scientists to challenge assumptions and build on collective knowledge. Challenges and Opportunities in a Connected World The scientific method faces hurdles: publication pressures, funding limitations, and reproducibility issues. Centralized systems paywalled journals, slow peer reviews can restrict access and collaboration. Decentralized science (DeSci), powered by Web3, offers solutions. Blockchain and decentralized platforms can make science more transparent and inclusive. For example: •Open Data Sharing: Blockchain ensures immutable, accessible research data, fostering global collaboration. Solana-based projects are already promoting DeSci awareness through decentralized repositories. •Tokenized Funding: Web3 enables crowdfunding and incentives, reducing dependence on traditional grants. •On-Chain Peer Review: Decentralized platforms can speed up reviews, rewarding fairness with tokens. Integrating the scientific method with #DeSci preserves rigor while accelerating discovery. Imagine hypotheses tested on decentralized platforms, data openly verified, and findings instantly accessible a vision aligned with the method’s focus on transparency. The Scientific Method in a Web3 Future As #Web3 and #DeSci grow, the scientific method can evolve further. Smart contracts could standardize experiments, AI on blockchain could generate hypotheses, and decentralized communities could validate results in real time. The scientific method’s emphasis on skepticism and validation will guide DeSci, ensuring integrity.

Rethinking Peer Review: A Decentralized System for Science Peer review, the cornerstone of scientific validation, is riddled with flaws. Controlled by a handful of publishers like Elsevier, Springer, and Wiley, it’s expensive, opaque, and biased. A 2021 study valued the academic publishing market at $19 billion annually, yet researchers who write, review, and edit papers receive no compensation. The process favors prestigious institutions, delays discoveries, and locks knowledge behind paywalls. A decentralized peer review system, leveraging blockchain technology, offers a transparent, equitable alternative that could reshape how science is validated. The Flaws of Centralized Peer Review The current system is a bottleneck. Publishers charge universities and researchers thousands of dollars to publish or access papers, Elsevier alone reported $3.6 billion in revenue in 2022. Meanwhile, reviewers volunteer their time, often under pressure to meet tight deadlines. Bias is well-documented: a 2019 study in Nature found that papers from top-tier institutions were 20% more likely to be accepted than equivalent submissions from lesser-known ones. Gender and geographic disparities persist, with researchers from the Global South facing higher rejection rates. Opacity compounds the issue. Editorial decisions are rarely disclosed, leaving authors guessing why papers were rejected. Conflicts of interest, such as reviewers favoring colleagues, go unchecked. The process is also slow—delays of six months to a year are common, stalling progress in fast-moving fields like epidemiology or renewable energy. Paywalls further limit access, with single articles costing $30-$50, excluding independent researchers or underfunded institutions. A decentralized system, built on blockchain and governed by community incentives, addresses these problems by prioritizing transparency, fairness, and efficiency. A Decentralized Peer Review Model ⁉️Here’s how it could function: Submission on a Blockchain: Researchers submit papers to a blockchain-based platform, such as one built on Ethereum or a layer-2 network like Polygon for lower costs and scalability. Each paper is timestamped, cryptographically signed, and stored on a decentralized file system like IPFS (InterPlanetary File System), ensuring immutability and open access. Authors pay a modest fee in cryptocurrency (e.g., $10-$50) to cover network costs, a fraction of the $2,000-$5,000 charged by traditional journals. Anonymous Review with Reputation Tokens: Reviewers, verified as researchers through decentralized identities (DIDs) tied to publication records or institutional affiliations, volunteer to evaluate papers. Smart contracts assign reviewers using algorithms that match expertise based on keywords, citation histories, or machine learning models trained on academic profiles. Reviews are submitted anonymously and recorded on the blockchain. Quality is assessed by metrics like depth, clarity, and adherence to community standards, with high-quality reviewers earning reputation tokens. These tokens can be used to submit papers, access premium platform features, or traded on decentralized exchanges. Community Validation: After reviews, the broader research community votes on a paper’s validity using quadratic voting, where votes are weighted by reputation tokens. This balances the influence of senior researchers with input from newer voices, reducing domination by entrenched elites. Accepted papers are published on the platform, freely accessible, with a transparent ledger of reviews, revisions, and voting outcomes. Governance and Incentives: The platform operates as a Decentralized Autonomous Organization (DAO), where token-holders vote on policies, such as review criteria, dispute resolution, or token distribution. To prevent manipulation, anti-Sybil measures—like proof-of-expertise via ORCID IDs or publication histories—ensure only qualified researchers participate. Reviewers are motivated by tokens and a public reputation score, which could influence funding, hiring, or collaborations. Authors benefit from faster publication and global visibility without paywalls. Why It’s Better This system tackles the core issues of traditional peer review: ▪️Reduced Bias: Anonymity and algorithmic matching minimize favoritism toward prestigious institutions or well-known authors. Quadratic voting amplifies underrepresented researchers, such as those from Africa or Southeast Asia, who often face systemic barriers. A 2020 study in PLOS ONE noted that 70% of published research originates from just 20 countries; decentralization could diversify this. ▪️Greater Transparency: Every action—submission, review, voting—is logged on the blockchain, publicly verifiable. This eliminates hidden editorial decisions and exposes conflicts of interest. Researchers can audit the process, fostering trust. ▪️Lower Costs: By removing publishers, the system slashes expenses. Instead of $3,000 to publish or $35 to read an article, knowledge is free or nearly so. Universities could redirect billions saved from journal subscriptions to research or infrastructure. ▪️Faster Science: Automation through smart contracts streamlines workflows. Reviewer assignment, feedback collection, and publication could take weeks instead of months, accelerating discoveries in critical fields like cancer research or climate modeling. Real-World Foundations Efforts toward decentralization are underway. #DeSci Labs is developing blockchain-based tools for scientific collaboration, including peer review prototypes. The Ocean Protocol enables decentralized data marketplaces, used by projects like marine biology research, showing how blockchain can manage scientific assets. PubPub and Scholastica, while not fully decentralized, experiment with open peer review, hinting at demand for alternatives. The EU’s 2023 mandate for open-access publicly funded research by 2024 pressures publishers, creating an opening for decentralized systems. Challenges and Criticisms Scaling a blockchain platform is technically complex. Ethereum’s high gas fees (though mitigated by layer-2 solutions) and IPFS’s storage limitations require robust engineering. Ensuring reviewer anonymity while verifying expertise is delicate—DIDs must balance privacy with accountability. Token incentives could attract bad actors, like reviewers inflating scores for profit. A 2022 analysis of blockchain-based systems noted that 15% of decentralized platforms faced Sybil attacks, underscoring the need for strong safeguards. Cultural resistance is another hurdle. Researchers, tenure committees, and funders prioritize legacy journals like Science or The Lancet for prestige. A 2023 survey by ResearchGate found 62% of academics reluctant to adopt new publishing models due to career concerns. Transitioning requires incentives, like universities valuing decentralized publications in hiring or governments tying funding to open-access contributions. Critics might argue that decentralization risks quality control, with less editorial oversight leading to subpar papers. However, community validation and reputation-based incentives can maintain rigor, as seen in open-source software communities like Linux, where peer scrutiny ensures excellence. Another concern is accessibility—cryptocurrency fees could exclude researchers in low-income regions, though token subsidies or grants could address this. Looking Ahead Picture a scientist in Jakarta uploading a study on dengue fever to a decentralized platform. Within weeks, experts from Berlin and São Paulo review it, their feedback transparent. The community validates it, and it’s published, free for clinics worldwide. She earns tokens, enhancing her career, while reviewers gain reputation. No publishers profit, biases diminish, and science accelerates. This system is not just a dream. The technology blockchain, smart contracts, decentralized storage exists. Pilot projects are emerging, and open-access mandates are shifting norms. By prioritizing transparency, equity, and speed, decentralized peer review can restore science’s core mission: advancing knowledge for all. The path forward lies in building platforms, testing incentives, and convincing researchers to embrace a system that serves them, not publishers. #DeSci $Met

Summary and Outlook In summary, recent human studies provide both hopeful and cautious notes about metformin as an anti-aging intervention. Observational analyses consistently find that people taking metformin (usually for diabetes) tend to develop fewer age-related diseases and live longer in good health . Yet observational data can only suggest correlation, not causation. Small randomized trials have begun to test metformin in specific aging-related domains: short-term treatment can induce gene expression changes associated with healthier aging , and preliminary trials in pre-dementia show improved memory performance with metformin . These hint that metformin might beneficially modulate certain aging processes in humans. On the other hand, more rigorous trials so far have shown no effect on some functional outcomes (e.g. no improvement in frailty or walking speed) and even potential downsides like gastrointestinal intolerance or blunted muscle gains in older individuals . No study to date has proven that metformin increases human lifespan – that remains an open question . Experts emphasize that evidence for longevity benefits is still inconclusive and likely indirect: metformin may extend life primarily by preventing or delaying diseases (diabetes, heart disease, cancer, etc.), rather than by slowing aging in a more fundamental way . The coming years should bring much clearer answers. Results from larger controlled trials (such as TAME and MAP) are eagerly awaited to determine if metformin can broadly improve healthspan or lower the risk of age-related chronic conditions in diverse, aging populations. These studies will also monitor biomarkers to see if biological aging rates are altered. If successful, metformin could become the first widely-available drug to target aging itself, marking a new era of “geroprotective” medicine. Even if outcomes are mixed, the knowledge gained will inform how we approach aging therapeutics – perhaps revealing subgroups who benefit most or guiding combination therapies (for example, pairing metformin with lifestyle interventions or other anti-aging drugs). In conclusion, metformin’s anti-aging promise is supported by encouraging human data on multiple fronts, but definitive proof requires the ongoing large-scale trials. Until then, metformin remains an intriguing candidate to improve longevity and healthspan, warranting the reliable clinical scrutiny it is now receiving.

These early trials hint that metformin might have neurological benefits that translate into slight cognitive improvements, at least for metabolic-related cognitive impairment. Building on this, a larger ongoing trial is now investigating metformin for prevention of Alzheimer’s in a broader population. The Metformin in Alzheimer’s Dementia Prevention (MAP) study is a Phase 2/3 multicenter trial launched in 2021. It plans to enroll about 326 non-diabetic adults (ages 55–90) with either early MCI or late MCI, who are overweight (a state of insulin resistance that metformin can target) . Participants take extended-release metformin (target dose 2,000 mg/day) or placebo for ~18 months, and the primary outcome is change in memory performance on a standardized test, with secondary endpoints including a composite cognitive score and brain MRI measures . This trial (taking place at over 20 U.S. centers) will help determine if metformin truly slows cognitive decline in at-risk elders. Results are not yet published as the trial is likely still ongoing. If positive, metformin could become one of the first medications to slow progression from MCI to Alzheimer’s, thereby extending cognitive healthspan. The TAME Trial and Other Large-Scale Efforts While small trials have examined surrogate markers, definitive proof of metformin’s geroprotective effects requires large, long-term studies. The TAME (Targeting Aging with Metformin) trial is a groundbreaking endeavor intended to test whether metformin can delay the onset of multiple chronic diseases in aging adults. TAME is designed as a six-year placebo-controlled trial across 14 research centers, enrolling over 3,000 healthy adults ages 65–79 . Instead of focusing on one disease, TAME’s outcome is the occurrence of any of several major age-related conditions (including cardiovascular events, cancer, dementia, and death) . The idea is that by targeting fundamental aging biology, metformin might simultaneously postpone or compress the onset of many diseases of aging, thereby prolonging healthy lifespan . In essence, TAME will test if aging itself can be treated as a unified condition, rather than treating each disease separately. If metformin delays the time until participants develop any chronic disease or functional impairment, it would be a landmark proof-of-concept that aging rate is modifiable in humans. As of 2024, however, TAME had not yet been launched; researchers have faced challenges securing funding for such an unprecedented trial of a generic drug . Government and philanthropic organizations have pledged portions of the required ~$65 million budget, and once fully funded, TAME is expected to begin*** . Geroscientists are hopeful that TAME will not only clarify metformin’s benefits but also pave the way for FDA to recognize “aging” as an indication for future drug approvals . In addition to TAME, other large-scale studies reflect the growing effort to validate metformin’s anti-aging potential. The aforementioned MAP trial in cognitive aging is one such effort (hundreds of patients over 1–2 years). Another example was the planned GLINT trial in the U.K., which aimed to enroll ~12,000 people with pre-diabetes to see if metformin prevents cardiovascular events over 5+ years . (GLINT’s feasibility phase was completed, but the full trial’s status remains uncertain.) Even if not explicitly framed as “anti-aging,” trials like these address age-related outcomes (heart disease, dementia) in non-diabetic populations, testing metformin as a preventive therapy. Ongoing research is also examining metformin’s effects on various biomarkers of biological aging – from inflammatory factors to epigenetic “aging clocks.” For instance, metformin is known to raise levels of GDF15, a hormone associated with longevity pathways, and higher GDF15 has been linked to better cardiovascular outcomes in metformin users .

Metformin’s Anti-Aging Effects: Recent Human Trial Evidence Introduction Metformin, a safe and inexpensive drug long used to treat type 2 diabetes, has drawn intense interest as a potential anti-aging therapy. Over the past decade, researchers observed surprising health benefits in metformin users – including lower rates of cancer, heart disease, and cognitive decline – hinting that it might slow age-related diseases . In animals, metformin can delay aging and extend lifespan, and it influences fundamental aging pathways (e.g. nutrient sensing, inflammation) . These findings spurred the design of clinical trials to test metformin’s effects on aging in humans. Notably, the Targeting Aging with Metformin (TAME) trial was proposed as the first large study to see if an aging process can be treated like a disease . Below, we summarize recent human studies (2019–2024) – including observational analyses and randomized controlled trials – that have evaluated metformin’s impact on biomarkers of aging, healthspan (healthy years of life), and age-related conditions. Epidemiological Evidence in Humans Large observational studies in people have provided foundational evidence linking metformin to healthier aging. For example, a meta-analysis of dozens of studies found that diabetics on metformin had a significantly lower risk of developing various cancers (including gastrointestinal, urologic, and blood cancers) compared to those not on metformin . Another study in the U.K. reported that metformin use in diabetics was associated with reduced incidence of dementia and mild cognitive impairment, as well as improved cardiovascular outcomes like lower rates of cardiovascular death . Intriguingly, a landmark retrospective analysis of over 180,000 adults in a British database found that patients with type 2 diabetes on metformin survived as long as (or even slightly longer than) age-matched non-diabetics, despite having more health problems – whereas diabetic patients on another drug (sulfonylurea) had shorter survival . This suggests metformin may extend healthspan by reducing disease burden, essentially allowing diabetics to live as long and healthily as people without diabetes. However, these associations are not proof of causation . Factors like underlying health or selection biases could play a role. Thus, while epidemiology hints that metformin users have fewer age-related illnesses, clinical trials are needed to confirm if metformin directly causes healthier aging. Randomized Trials on Aging Biomarkers and Healthspan Metformin in Longevity Study (MILES) – Biomarker Changes The MILES trial was one of the first clinical studies to examine metformin’s effects on molecular aging markers in humans. In this small randomized crossover trial, 14 older adults (without diabetes, but with elevated blood sugar) took metformin (up to 1700 mg/day) for 6 weeks and acted as their own controls . Researchers biopsied skeletal muscle and fat tissue to profile gene expression (“transcriptomic” changes) before and after metformin. The short-term metformin treatment triggered significant changes in hundreds of genes in muscle (647 genes) and dozens of genes in fat (146 genes) involved in pathways relevant to aging . For instance, metformin upregulated genes related to DNA repair and cellular metabolism and downregulated some related to age-linked metabolic decline (e.g. genes in mitochondrial pathways and lipid metabolism) . These shifts in gene expression suggest that metformin can induce a more “youthful” or protective profile in tissues. The authors concluded that this was preliminary evidence of metformin modifying fundamental aging pathways in humans . While MILES was very small and short in duration, it provided a proof-of-concept that biomarkers of aging at the molecular level (like transcriptomic profiles) can be favorably altered by metformin in older adults.

Why would we do such a thing? You are just thinking only yourself! In this project team owns only 2% of the supply, we did not make any sales (even while we were at 5-6m) and made no profit. Also we planned an experiment via our own pockets. And you are suggesting that we need to buy again from our own pockets and burn this investment. What a selfish thing to say.

@metforminsol Şu an düşükten geri alıp arzın %70 yakmalısınız hem dolaşımdaki arz kısıltlı olur hemde dahada değerli olur

Impressive progress from $Scihub community Sci-Net (sci-net.xyz) Open Source Science

Metformin: decelerates biomarkers of aging clocks nature.com/articles/s4139… pubmed.ncbi.nlm.nih.gov/39270656/?dopt…

Price is not under our control From the beginning we had 2% of the supply and we are holding all the tokens we have since we launched. There were 3 team wallets, recently we gather all supply to 8BuZUaod8TXFtzqMctXR5HFYhfvVCyCMnyn6Ugn8iqkU (And also we add 0.5% more to team wallet) So, no we didnt sell any supply from team wallets.

@metforminsol Siz elinizdekileri sattınızmı fiyat yerlerde size guvenmiştim

@SciHubFans We will try it asap!

SCAICH DEEP RESEARCH Live Demo! A Revolutionary AI-Powered Research Tool! End-to-End Academic Paper Analysis System! Watch the video to experience the seamless workflow: From paper search → AI interpretation → AI-powered Q&A. Supports 90M+ papers across major platforms including Sci-Hub & arXiv! #SciHub #OpenScience #AI4SCI